True North to acquire 2.4% stake in Biocon Biologics
Deal values Biocon Biologics at $3 billion
True North buys into Biocon Biologics, deal values firm at around $3.5 billion
True North has acquired about 3 per cent of Biocon Biologics I...
Zumutor Biologics gets $4 million in fresh funds
The company said the capital will be used for the process of new drug filing of its lead mol...
Biocon elevates M B Chinappa as CFO of biosimilar subsidiary
M B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been tasked to drive financial performance of the company and improve profitability and manage anticipated risks in the journey of achieving the $1 billion revenue target in FY22, said the company in a press release.
Biocon gets EIR from USFDA for Bengaluru biologics unit
Biopharma major Biocon reportedly received an Establishment Inspection Report (EIR) from US-FDA for its biologics drug product unit at Bengaluru after having undergone good manufacturing norms earlier in August. CEO Christine Hamacher said, "The EIR for this facility reaffirms our manufacturing capabilities for high quality biosimilars".
ET Startup Awards 2019: Tricog wins Top Innovator category
Amitabh Kant, the CEO of Niti Aayog and a jury member, said Tricog was playing a path-breaking role in diagnosis.
Biologics enter top selling drugs’ list
Biologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out of the top slots.
Piramal, Fujifilm Diosynth tie up for biopharmaceuticals
Piramal Enterprises today said its healthcare vertical has tied up with Fujifilm Diosynth Biotechnologies for co-operation in biopharmaceuticals for developing new therapies, including that of cancer.
Ranbaxy launches arthritis drug Infimab in India
Infimab has been introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement.
Vyome Biosciences closes $8 million funding round
Proceeds from the Series B round of funding will be used to drive the completion of critical milestones of US Food and Drug Administration filings.
India emerges as leader in global vaccine market: Government
India has emerged as a global leader in vaccines with about one-third share of the total market, a senior government official said today.
Intas Pharmaceutical launches low cost drug 'Mabtas' for cancer treatment
Intas Pharmaceutical today said it has launched 'Mabtas' a new low cost drug for treating cancer in India.
Pharmaceutical Export Promotion Council of India seeks clarity from US on new generic drug fee norms
Pharmexcil has sought clarity from the United States Food and Drug Administration (USFDA ) on the new generic drug user fee norms.
GE Healthcare to acquire PAA Laboratories
GE Healthcare said that it has reached an agreement to acquire PAA Laboratories that develops and supplies cell culture media for biomedical research.
Intas ex-employee objects to amalgamation plan
An affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, in Gujarat High Court.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service